INCLUSIVE
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu
4376
Cube
7112
(Q2)2024/06/30 | (Q1)2024/03/31 | (FY)2023/12/31 | (Q4)2023/12/31 | (Q3)2023/09/30 | (Q2)2023/06/30 | (Q1)2023/03/31 | (FY)2022/12/31 | (Q4)2022/12/31 | (Q3)2022/09/30 | |
---|---|---|---|---|---|---|---|---|---|---|
營業總收入 | 0.89%21.63億 | -0.31%21.16億 | -0.56%84.83億 | -0.32%21.15億 | -1.40%21.02億 | 0.86%21.44億 | -1.36%21.23億 | -12.73%85.31億 | -2.42%21.21億 | -12.50%21.32億 |
主營業務成本 | -1.81%10.69億 | 0.80%10.74億 | 4.97%44.77億 | 6.92%11.66億 | 2.05%11.58億 | 6.25%10.89億 | 4.81%10.65億 | -30.20%42.66億 | -12.02%10.9億 | -25.21%11.34億 |
毛利 | 3.68%10.94億 | -1.42%10.42億 | -6.08%40.06億 | -7.98%9.49億 | -5.34%9.45億 | -4.16%10.55億 | -6.88%10.57億 | 16.40%42.65億 | 10.30%10.31億 | 8.47%9.98億 |
營業費用 | -4.50%9.66億 | -7.89%9.56億 | -7.19%37.81億 | -13.08%8.75億 | -10.96%8.57億 | -2.20%10.11億 | -3.06%10.37億 | 3.19%40.74億 | -20.30%10.07億 | 18.40%9.63億 |
營業利潤 | 194.77%1.28億 | 333.97%8,680.2萬 | 17.44%2.25億 | 199.58%7,410.6萬 | 150.03%8,724.4萬 | -34.72%4,330.9萬 | -69.38%2,000.2萬 | 167.38%1.91億 | 107.54%2,473.7萬 | -67.28%3,489.4萬 |
營業外利息收入與支出淨額 | -33.77%-61萬 | -6.75%-49萬 | 19.41%-188.1萬 | 6.55%-49.9萬 | 15.86%-46.7萬 | 15.08%-45.6萬 | 35.17%-45.9萬 | 67.73%-233.4萬 | 31.10%-53.4萬 | 29.12%-55.5萬 |
營業外利息收入 | --0 | 0.00%1,000 | 50.00%3,000 | --0 | 100.00%2,000 | --0 | 0.00%1,000 | -93.55%2,000 | 13.04%-4萬 | -96.67%1,000 |
營業外利息支出 | 33.77%61萬 | 6.74%49.1萬 | -19.35%188.4萬 | 1.01%49.9萬 | -15.65%46.9萬 | -20.97%45.6萬 | -35.12%46萬 | -67.84%233.6萬 | -32.24%49.4萬 | -31.61%55.6萬 |
投資淨收益 | ||||||||||
被指定為現金流套期的金融工具損益 | ||||||||||
終止確認可供出售金融資產損益 | -0.92%-54.7萬 | -27.71%-476.6萬 | -281.66%-537.7萬 | -105.24%-55.4萬 | 19.97%-54.9萬 | 20.06%-54.2萬 | 40.20%-373.2萬 | 103.73%296萬 | 114.78%1,056.5萬 | 89.32%-68.6萬 |
聯營企業及其他參股權益產生的收益 | -1,239.1萬 | |||||||||
特殊收入(費用) | 135.61%99.9萬 | 2,149.47%641.1萬 | -80.05%247.6萬 | -87.22%135.8萬 | -24.68%40.9萬 | -24.69%42.4萬 | -58.45%28.5萬 | 236.48%1,241.4萬 | 263.97%1,062.2萬 | 134.83%54.3萬 |
減:其他特殊費用 | --0 | -943.37%-565.9萬 | 113.15%91.2萬 | --24.1萬 | --0 | --0 | --67.1萬 | -322.42%-693.5萬 | ---- | ---- |
減:勾銷 | -135.61%-99.9萬 | 21.34%-75.2萬 | 38.16%-338.8萬 | 56.63%-159.9萬 | 24.68%-40.9萬 | 24.69%-42.4萬 | -39.36%-95.6萬 | -191.65%-547.9萬 | -156.92%-368.7萬 | -171.50%-54.3萬 |
其他營業外收入(費用) | -54.30%8.5萬 | -87.38%16.7萬 | -16.54%174.1萬 | -58.47%4.9萬 | 232.73%18.3萬 | 47.62%18.6萬 | -25.97%132.3萬 | 582.87%208.6萬 | 281.54%11.8萬 | 121.24%5.5萬 |
稅前利潤 | 197.27%1.28億 | 405.86%8,812.5萬 | 7.36%2.22億 | -29.36%7,446萬 | 297.17%8,682.1萬 | -1.78%4,292萬 | -50.87%1,742.1萬 | 148.88%2.06億 | 124.39%1.05億 | -72.90%2,186萬 |
所得稅 | -391.67%-1,064萬 | 144.02%1,574.4萬 | -286.63%-1,954.2萬 | 73.81%-793萬 | 95.29%2,050.5萬 | -58.35%364.8萬 | -266.40%-3,576.5萬 | 112.87%1,047.1萬 | -4,444.62%-3,028.2萬 | 962.78%1,050萬 |
除稅後利潤 | 251.97%1.38億 | 36.09%7,238.1萬 | 23.07%2.41億 | -39.28%8,239萬 | 483.77%6,631.6萬 | 12.40%3,927.3萬 | 280.88%5,318.6萬 | 145.86%1.96億 | 131.35%1.36億 | -86.12%1,136萬 |
持續經營利潤 | 251.98%1.38億 | 36.09%7,238.1萬 | 23.07%2.41億 | -39.28%8,239萬 | 483.77%6,631.6萬 | 12.40%3,927.2萬 | 280.85%5,318.6萬 | 145.86%1.96億 | 131.35%1.36億 | -86.12%1,136萬 |
歸屬于少數股東的淨利潤 | 0 | |||||||||
歸屬於母公司的淨利潤 | 251.97%1.38億 | 36.09%7,238.1萬 | 23.07%2.41億 | -39.28%8,239萬 | 483.77%6,631.6萬 | 12.40%3,927.3萬 | 280.88%5,318.6萬 | 150.43%1.96億 | 131.35%1.36億 | -86.12%1,136萬 |
優先股派息 | ||||||||||
其他優先股派息 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
歸屬于普通股股東的淨利潤 | 251.97%1.38億 | 36.09%7,238.1萬 | 23.07%2.41億 | -39.28%8,239萬 | 483.77%6,631.6萬 | 12.40%3,927.3萬 | 280.88%5,318.6萬 | 150.43%1.96億 | 131.35%1.36億 | -86.12%1,136萬 |
總派息金額 | ||||||||||
基本每股收益 | 250.27%12.82 | 35.69%6.73 | 23.04%22.48 | -39.29%7.68 | 483.02%6.18 | 12.27%3.66 | 281.54%4.96 | 150.44%18.27 | 131.35%12.65 | -86.11%1.06 |
稀釋每股收益 | 250.00%12.81 | 35.08%6.7 | 22.17%22.32 | -39.29%7.68 | 483.55%6.18 | 12.37%3.66 | 281.54%4.96 | 150.44%18.27 | 131.35%12.65 | -86.12%1.059 |
每股派息 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
貨幣單位 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 |
會計準則 | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |